| |
Whole cohort(n = 43)
|
AKI(n = 21)
|
Non-AKI(n = 22)
|
P-value
|
|---|
|
Age at HSCT, years, median (IQR)
|
5.5 (4.1–10.8)
|
5.5 (4.2–14.4)
|
5.2 (4.1–7.8)
|
0.37
|
|
Sex, Male, n (%)
|
28 (65)
|
14 (67)
|
14 (64)
|
0.84
|
|
Indication for HSCT
|
|
Malignant
|
34 (79)
|
18 (86)
|
16 (73)
|
0.46
|
|
Conditioning regimen, n (%)
|
|
Calcineurin inhibitor
|
4 (9)
|
2 (10)
|
2 (9)
|
1.00
|
|
TBI use
|
22 (51)
|
15 (71)
|
7 (32)
|
< 0.01
|
|
Stem cell source, n (%)
|
|
Bone marrow
|
19 (44)
|
9 (43)
|
10 (45)
|
0.86
|
|
Peripheral blood
|
21 (49)
|
9 (43)
|
12 (55)
|
0.44
|
|
Umbilical cord
|
3 (7)
|
3 (14)
|
0 (0)
|
0.11
|
|
Donor source, n (%)
|
|
Autologous
|
20 (46)
|
7 (33)
|
13 (59)
|
0.091
|
|
MRD
|
5 (12)
|
1 (5)
|
4 (18)
|
0.35
|
|
MUD
|
18 (42)
|
13 (62)
|
5 (23)
|
< 0.01
|
|
Acute GVHD, n (%)
|
20 (47)
|
12 (67)
|
8 (36)
|
0.17
|
|
I
|
8 (19)
|
4 (18)
|
4 (18)
|
1.00
|
|
II – IV
|
12 (28)
|
8 (38)
|
4 (19)
|
0.19
|
- HSCT, hematopoietic stem cell transplantation; TBI, total body irradiation; MRD, matched related donor; MUD, matched unrelated donor; GVHD, graft-versus-host disease
